Margarida Maia, PhD,  science writer—

Overactive T2 inflammation, a type of immune response linked to asthma, may be associated with worse symptoms of cystic fibrosis (CF), a finding that could pave the way for using anti-asthmatics for CF, a study suggests. The study, “Association between Cystic Fibrosis exacerbations, lung function, T2 inflammation and…

Use of Kaftrio (elexacaftor/tezacaftor/ivacaftor) may help people with cystic fibrosis (CF) and the F508del mutation in both CFTR gene copies live to a median age of 71.6 and possibly longer if treatment is started in adolescence, a U.K.-based study reported. In a scenario where treatment with Kaftrio — sold…

An antibiotic susceptibility kit, called AtbFinder, helped doctors choose effective antibiotics against lung infection caused by hard-to-treat Pseudomonas aeruginosa in four hours, and this led to fewer hospital stays, less use of systemic antibiotics, and better outcomes for people with cystic fibrosis (CF), according to a small…

BX004, BiomX’s experimental phage cocktail — a treatment that uses certain viruses to kill disease-causing microorganisms — was seen to reduce the number of Pseudomonas aeruginosa bacteria present in the lungs of people with cystic fibrosis (CF) in the first part of a small trial. The nebulized…

Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor marketed as Trikafta in the U.S., may relieve much of the discomfort that’s sometimes experienced by people with cystic fibrosis (CF) in the nose and the air-filled cavities around it, called sinuses, a German study found. The study, “Effects…

Nearly two-thirds of the people with cystic fibrosis (CF) in the U.S. are under financial hardship, and many face unmet medical needs, meaning their treatment is not being addressed adequately. Researchers with George Washington University and the Cystic Fibrosis Foundation, who conducted this analysis into the cost of…

Taking Trikafta (elexacaftor/tezacaftor/ivacaftor) may lead to only a mild rise in liver enzymes in people with cystic fibrosis (CF)-related liver disease, a study found. This is likely not a clinically significant change, “and should not be a barrier to prescription,” the researchers wrote in the study, “Longitudinal effects…

Nearly 8% of people with cystic fibrosis (CF) may be infected with nontuberculous mycobacteria (NTM), a type of bacteria in the environment, a meta-analysis study has found. Researchers observed that the number of cases has surged across the world over the last few years. The bacteria can cause infection…

Trikafta (elexacaftor/tezacaftor/ivacaftor) was seen to keep lung function from getting worse in people with cystic fibrosis (CF) for up to two years, a study found. These findings counter previous studies wherein the active ingredients in Trikafta, alone or in combinations of two, were seen to slow, but not…

Sionna Therapeutics is forging ahead in the new year with its preclinical and clinical programs aimed at developing small molecules — such as SION-638 — as possible treatments for cystic fibrosis (CF). An ongoing Phase 1 trial, now enrolling participants, is testing SION-638 in healthy volunteers. Dosing…